Objective: To explore the efficiency of single application of lobaplatin in tran-scatheter arterialchemoembolization (TACE) for patients with a primary hepatic carcinoma who were unable or unwilling toundergo surgery.
Methods: 173 patients with primary hepatic carcinoma diagnosed by imaging or pathology wererandomly divided into experimental and control groups and respectively treated with lobaplatin and pirarubicinhydrochloride as chemotherapeutic drugs for TACE. The amount of iodipin was regulated according to thetumor number and size, and then gelatin sponge or polyvinyl alcohol particles were applied for embolisms. Theefficiency of treatment in the two groups was compared with reference to survival time and therapeutic response.
Results: The experimental group (single lobaplatin as chemotherapy drug) was superior to control group (singlepirarubicin hydrochloride as chemotherapy drug) in the aspects of survival time and therapeutic response, withstatistical significance.
Conclusions: Single lobaplatin can be as a chemotherapy drug in TACE and has betterefficiency in the aspects of mean survival time and therapeutic response, deserving to be popularized in the clinic.